February 21, 2024
Anti-Neprilysin Market Growth

Pharmaceutical Segment is the largest segment driving the growth of Anti-Neprilysin Market

The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Anti-Neprilysin drugs are mainly used for the treatment of heart failure. They work by blocking the enzyme neprilysin and increasing levels of natriuretic peptides which help relax blood vessels and sodium excretion from the body.

Market key trends:

One of the major trends in the anti-neprilysin market is the increasing prevalence of heart failure worldwide. As per the American Heart Association, over 6 million adults in the U.S. suffer from heart failure. The condition is more common among elderly people. With rising life expectancy, the number of people suffering from heart failure is expected to increase significantly in future, thereby driving the demand for anti-neprilysin drugs for its treatment and management.

Market key trends:

The anti-neprilysin market iswitnessinghigh growth owing to the rising prevalence of heart failure across the globe. As per stats, nearly 6.2 million American adults suffer from heart failure. Rising geriatric population is another factor contributing to the growth of this market as aged people are more susceptible to chronic heart conditions. Moreover, drugmakers are actively investing in R&D activities to develop better anti-neprilysin drugs with improved efficacy and safety profiles which is bolstering market expansion.

SWOT Analysis

Strengths: Existing drugs have demonstrated efficacy in improving symptoms in heart failure patients. Drugs also help in reducing mortality rates.

Weaknesses: High development costs involved due to lengthy clinical trials. Potential side effects of drugs like hypotension and angioedema.

Opportunities: Rising incidences of heart diseases creates demand for improved treatment options. Several pipeline drugs are under development.

Threats: Patent expiries of major drugs resulting in lower profits. Price controls and regulatory hurdles also restrict growth.

Key Takeaways

The global anti-neprilysin market is expected to witness high growth, exhibiting CAGR of 4.6% over the forecast period, due to increasing geriatric population suffering from chronic heart ailments.

Regionally, North America accounts for the largest share in the anti-neprilysin market due to growing prevalence of heart diseases. Europe holds second largest market share owing to rising healthcare spending. Asia Pacific exhibits potential growth due to improving access to healthcare facilities.

Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. BIOPROJET leads the market with its blockbuster brand Entresto used for treatment of chronic heart failure. Novartis also has a significant share with its product LCZ696.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it